Alkermes (ALKS) EBITDA Margin Growth (1y) (2011 - 2026)
Alkermes (ALKS) EBITDA Margin Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.20 Bn | 43.24 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.43 Bn | 39.78 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 32.03 Bn | 30.35 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 22.42 Bn | 19.76 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 12.05 Bn | 11.52 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.92 Bn | - | - |
| 10 | Alkermes | 8.06 Bn | 7.41 Bn | 397.90 Mn | -2,010.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,010.00 |
| Mar 31, 2026 | -1,679.00 |
| Dec 31, 2025 | -2,273.00 |
| Sep 30, 2025 | -510.00 |
| Jun 30, 2025 | -373.00 |
| Mar 31, 2025 | -786.00 |
| Dec 31, 2024 | 2,336.00 |
| Sep 30, 2024 | 429.00 |
| Jun 30, 2024 | -1,803.00 |
| Mar 31, 2024 | 1,618.00 |
| Dec 31, 2023 | -2,347.00 |
| Sep 30, 2023 | 191,845.00 |
| Jun 30, 2023 | 112,234.00 |
| Mar 31, 2023 | 573.00 |
| Dec 31, 2022 | -195.00 |
| Sep 30, 2022 | -188,835.00 |
| Jun 30, 2022 | -107,824.00 |
| Mar 31, 2022 | -301.00 |
| Dec 31, 2021 | 5,086.00 |
| Sep 30, 2021 | -266.00 |